While clinical evidence of combined degeneration of the bulbar and spinal motor neurons (MN) together with the corticospinal neurons (CSN) is required to diagnose Amyotrophic Lateral Sclerosis (ALS), preclinical studies have mostly concentrated on MN, leaving aside the CSN and their contribution to ALS onset and progression. Recent studies carried on ALS patients suggest that the disease may initiate in the motor cortex and spread to its projection targets, along the corticofugal axonal projections (including CSN), either via altered neuronal excitability and subsequent excitotoxicity, or via prion-like propagation of misfolded proteins. We recently provided first experimental arguments in favour of the corticofugal hypothesis of ALS, demonstrating that CSN and other subcerebral projection neurons were toxic in a context of ALS. Here, we aimed to determine how CSN may be detrimental to their downstream targets, and what governs their degeneration. To answer these questions, we took advantage of the
Introduction
Combined degeneration of corticospinal neurons (CSN) in the motor cortex, and motor neurons (MN) in the brainstem and spinal cord clinically defines amyotrophic lateral sclerosis (ALS), a terminal disease and the third most frequent neurodegenerative disease after Alzheimer's and Parkinson's diseases . If ALS is mostly sporadic, about 10% of patients have a familial history of the disease. The most common causative genes are C9ORF72, SOD1
(the first gene ever linked to ALS), FUS and TARDBP (Brown and Al-Chalabi, 2017; Chia et al., 2017) . These have greatly contributed to the development of cellular and animal models of the disease. Indeed, preclinical studies based on the numerous rodent models that followed the discovery of SOD1 in particular (Lutz, 2018) , and the more recent emergence of induced MN from ALS patients' iPSC (Guo et al., 2017) have allowed to establish a clear picture of the mechanisms involved in MN degeneration. Contrastingly, little is known at the moment about the mechanisms that govern CSN dysfunction and degeneration, and their role in disease onset and progression. The question is altogether central to ALS research, given the severity of the disease in comparison with diseases that affect only the MN (Kennedy's disease, adult-onset spinal and muscular atrophy) (Sorenson, 2012) , and timely, in the context of a renewed interest for the motor cortex in ALS clinical and preclinical research Eisen et al., 2017; Geevasinga et al., 2016) .
The pathological hallmark of the great majority of sporadic and familial ALS cases is the presence of intracytoplasmic inclusions of TDP-43, encoded by TARDBP, with the exception of familial SOD1 and FUS patients that display respectively SOD1 and FUS aggregates (Farrawell et al., 2015) . Detailed examination of the cerebral pathology indicated a greater frequency of aggregates in the motor cortex and its direct targets , which led to the emergence of the so-called « corticofugal hypothesis » that proposes an origin of the pathology in the motor cortex and a prion-like propagation of abnormal proteins along the corticofugal axonal projections . Another argument in favour of a cortical origin of the disease is the early cortical hyperexcitability that appears as an intrinsic feature of sporadic and familial amyotrophic lateral sclerosis (ALS) phenotypes, precedes the onset of MN dysfunction and correlates with ensuing MN dysfunction and degeneration . Interestingly, a recent study demonstrated that neuronal hyperexcitability was sufficient to induce cytoplasmic accumulation of TDP-43 (Weskamp et al., 2019) , linking for the first time hyperexcitability and pathology, and further supporting the earliness of cortical hyperexcitability in the cascade of pathogenic events that characterize ALS.
In order to test the corticofugal hypothesis in a controlled manner, we recently generated a mouse model that ubiquitously expresses a mutant of the murine Sod1 gene, a condition sufficient to develop ALS-like symptoms and premature death (Marques et al., 2019; Ripps et al., 1995) , but entirely lacks CSN and other cortical layer V subcerebral projection neurons (SubCerPN) , that, together with the cortical layer VI corticothalamic neurons, represents the major corticofugal output (Lodato et al., 2014) . We demonstrated that absence of CSN and related SubCerPN delayed disease onset, reduced weight loss and motor impairment, and increased the survival of Sod1 G86R mice, suggesting that SubCerPN and CSN in particular may carry detrimental signals to their downstream targets . Similar results had been previously obtained in the SOD1 G93A rat model of the disease upon knockdown of the transgene selectively in the neuronal populations of the motor cortex (Thomsen et al., 2014) .
What these studies did not address is how CSN may be toxic to their downstream targets, and what governs their degeneration. To answer these questions, we took advantage of the FloxedSOD1 G37R mouse model of ALS that allows genetic ablation of the mutant transgene in selected cells upon Cre-mediated recombination (Boillee et al., 2006) , and crossed it to the CrymCreER T2 mouse line that we purposely designed to genetically target CSN and other corticofugal projection neuron (CFuPN) populations. We demonstrate that excision of the mutant SOD1 G37R transgene from the CSN is sufficient to prevent their degeneration, but does not impact disease onset and progression. The data thus suggest that CSN degeneration mostly relies on cell-intrinsic mechanisms, and that the toxicity of the CFuPN to their downstream targets does likely not rely on the presence and propagation of misfolded proteins and aggregates. (C8267, Sigma) at the dose of 0.25 mg/g body weight. Males were used for survival and behavioural studies and histology. Mice were followed weekly, and disease progression was rated according to a clinical scale going from score 4 to 0, as previously described (Rouaux et al., 2007) . End-stage animals were euthanized upon reaching score 0, i.e. when they were no longer unable to roll over within 10 s after being gently placed on their back (Rouaux et al., 2007) . Disease onset was calculated as the time of peak of body weight.
Materials and Methods

Animals
Semi-quantitative PCR analyses and gel electrophoresis
Cortical layers were microdissected under a SMZ18 microscope (Nikon) from three adjacent 1 mm-thick coronal brain sections obtained using a stainless steel coronal brain matrix (Harvard Apparatus, MA). Cortical layers, spinal cord and brain stem were harvested, rapidly frozen in liquid nitrogen and stored at -80°C until use. Genomic DNA was extracted using the conventional phenol-chloroform/proteinase-K method. 0.5 µg of DNA was amplified under the same conditions used for genotyping (Boillee et al., 2006) . The PCR products were fractionated on a 3.0% agarose gel using 1X TAE buffer containing ethidium bromide and were visualized under UV light, and the gels were photographed using a UV gel documentation system. A 1 kbp DNA ladder molecular weight marker (Life Technologies, Rockville, MD) was run on every gel to confirm expected molecular weight of the amplification product. For quantification, band intensities were measured using ImageJ (NIH).
qPCR analyses
Cortical layers, spinal cord and muscle tibialis anterior were harvested and rapidly frozen in liquid nitrogen and stored at -80°C until analysis. Total RNA was extracted using TRIzol reagent (Invitrogen) and stainless-steel bead in a Tissue Lyser (Qiagen). 1 µg of RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad). Quantitative PCR (qPCR) was performed with the IQ SYBR Green Supermix (Bio-Rad). Gene expression was normalized by calculating a normalization factor using Gusb, Actb and Hsp90ab1 as reference genes for the nervous tissues, and H1h2bc, H2AC and H2AX as references genes for the muscular tissues. The following primer were used: 
Motor tests
For all motor tests, mice were trained from 24 to 25 weeks of age, and then followed from 26 weeks of age until death, on a daily basis for general health and neurological symptoms, and once a week for body weight, muscle grip strength inverted grid test and CatWalk. Each motor session consisted of three trials and the results represent the mean of these three trials. Muscle strength was measured using a strength grip meter (Bioseb, BIO-GS3). Four limbs hang test that allows measuring the ability of mice to use sustained limb tension to oppose gravitational force was used as previously described Carlson et al., 2016; Scekic-Zahirovic et al., 2017) . Mouse gait was analysed with the CatWalk XT (Noldus Information Technology) which generates numerous parameters for quantitative and qualitative analysis of individual footprint and gait (Vergouts et al., 2015) . Recordings were performed under the conditions previously described Scekic-Zahirovic et al., 2017) . Each mouse was allowed to cross freely the recording field of the runway with three independent attempts. Criteria for data collection were i) crossing the field in less than 10 seconds and ii) a walking speed variation of less than 60%. The six following gait and coordination parameters were analysed: Run Average and tibialis anterior muscles of both limbs for at least 2 minutes, as previously described (Rouaux et al., 2007) . For each muscle, a score of 0 (innervated) or 1 (denervated) was given, and the total scores of the four muscles were summed.
Tail spasticity
Tail spasticity of end stage mice was determined and quantified as previously described . Briefly, a monopolar needle electrode (Medtronic, 9013R0312, diameter 0.3 mm) was inserted in segmental tail muscles of paralyzed mice to record reflex activity.
Muscles spasms were evoked with mechanical stimulation of the tail. For quantification of the response, value of maximal amplitude (in mV) of LLR signal was measured after stimulation, using ImageJ (NIH).
In situ hybridization
The cDNA clone for mu Crystallin (Crym) is a kind gift from the Arlotta lab. Riboprobes were generated as previously described . Nonradioactive in situ hybridization was performed on 40 μm vibratome coronal brain sections 0.14 mm anterior to Bregma.
Selected sections were mounted on superfrost slides and processed using reported methods (Lodato et al., 2011) . Bright field 10X tiles images were acquired with an AxioImager.M2 microscope (Zeiss) equipped a high-resolution B/W camera (Hamamatsu), and run by the ZEN 2 software (Zeiss).
Retrograde labelling of the CSN
CSN were labelled as previously described (Marques et al., 2019 Immunohistochemistry was performed on brain and spinal cord sections at room temperature.
Sections were first immersed in 3% hydrogen peroxide (H 2 O 2 ) to remove the endogenous peroxidase activity, and washed with phosphate buffered saline (PBS), incubated with 5% horse serum and 0.5% triton X-100 in PBS for 30 min and incubated with primary antibody overnight.
After rinsing in PBS, sections were incubated with biotinylated secondary antibody for 2 hours, rinsed in PBS and incubated 1 hour with the Vectasatin ABC Kit (Vector Laboratories, PK7200).
Revelation was performed by incubating the sections in 0.075% 3, 3'-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, D5905) and 0.002% H 2 O 2 in 50mM Tris HCl.
For immunofluorescence, brain and spinal cord sections were heated at 80°C in citrate buffer pH6.0 for 30 min and incubated with 5% horse serum and 0.5% triton X-100 in PBS for 1 hour before being incubated with primary antibody overnight at 4°C. After rinsing in PBS, sections
were incubated with Alexa-conjugated secondary antibody for 2 hours, rinsed in PBS and water and mounted with DPX mounting solution (SIGMA, 06522-100ML).
The primary antibodies used in this study are the following: goat anti-Td-Tomato ( (1/500) and Alexa-conjugated (1/500) secondary antibodies were purchased from Jackson.
Images were captured using an AxioImager.M2 microscope (Zeiss) equipped with a structured illumination system (Apotome, Zeiss) and a high-resolution B/W camera (Hamamatsu), and run by the ZEN 2 software (Zeiss). Experimenters blinded to the genotypes performed the neuronal counts and NMJ assessments.
Brain histological analyses
Brains sections from Fluorogold injected animals were mounted on slides with DPX mounting solution (SIGMA, 06522-100ML). Fluorogold-positive neurons were manually counted, on both hemispheres, within layer V, from M2 medially to S1 laterally. IBA1 and GFAP intensities were quantified using ImageJ software (NIH, MD, USA). Three regions of interest (ROI) were created and used for all images. The three ROI were placed respectively over the cortical layers II/III and V and over the cingulate cortex for background. Background was substracted from intensities of the cortical layers II/III and V ROI. For each animal 2 pictures corresponding to each hemisphere were analysed. Serotonergic neurons were quantified from individual coronal sections located at Bregma -4.72 mm.
Spinal cord histological analyses
Lumbar (L2-L3) spinal motor neurons from two sections separated by 320 μm were mounted on slides, dried at 40°C on a hot plate for 3 hrs and stained with 1% toluidine blue solution for 1 min, rinsed with water, dehydrated and mounted. Two images per section (one per ventral horn) were captured and motor neurons (defined as cells with area larger than 350 μm 2 ) were quantified using ImageJ (NIH).
hSOD1, GFAP, IBA1 and P62 intensities were quantified using ImageJ software (NIH). For each image, ROI were manually drawn following the natural border between grey and white matter.
Intensities were quantified similarly to IBA1 and GFAP in the brain (see above).
Muscle histological analyses
Tibialis anterior muscles were dissected into bundles and processed for immunofluorescence using a combination of rabbit anti-synaptophysin (Eurogentec, 1/50) and rabbit antineurofilament antibodies (Eurogentec, 1/50) followed by an Alexa-conjugated donkey antirabbit 488 (Jackson, 1/1 000), and rhodamine conjugated α-bungarotoxin (Sigma-Aldrich, T0195), as previously described (Marques et al., 2019) . On average 100 NMJ per animals were examined.
Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism 6 (GraphPad, CA). Student's t-test was used for comparison between two groups, and 1-way or 2-way analysis of the variance, followed by Tukey's multiple comparison post hoc test were applied for three or more groups. For survival and disease onset analysis, animals were evaluated using log-rank test (Mantel-Cox). Fischer exact test was used to determine significant different proportion. Results were considered significant when p<0.05.
Results
Generation of Crym-CreER T2 mice
In order to test the effects of selective removal of an ALS-causing mutant gene from the CSN in mice, we first sought to generate a mouse line to restrict the expression of the Cre recombinase within the CFuPN populations composed of the layer V subcerebral projection neurons (SubCerPN) that include the discrete population of CSN, and the layer VI corticothalamic neurons. Within the cerebral cortex, expression of Mu-crystallin (Crym) was found restricted to CFuPN . We further confirmed this pattern of expression by conducting in situ hybridization analyses at postnatal days (P) P1 and P15, and in the adult mouse brain (Fig.   1a , and data not shown). At P15, Crym expression was detected in the cingulate cortex, the layer V of the motor and somatosensory cortex, the piryform cortex, the Olfactory Tubercule, and, at a lower level, in the layer VI of the cerebral cortex where corticothalamic neurons are located (Fig. 1a) . Crym expression was also detected in the most medial part of the caudate putamen, and the CA1 and CA2 regions of the hippocampus (Fig. 1a) . To verify that Crym was not expressed in the spinal cord, where lower motor neurons (MN) are located, we ran qPCR on mRNA extracted from the layer V of the cerebral cortex and the lumbar part of the spinal cord of 4 months old wild-type mice (Fig. 1b) . We did not detect Crym expression in the spinal cord (Fig. 1b) . We thus designed a knock-in mouse line to restrict the tamoxifen-inducible Cre recombinase (CreER T2 ) within the Crym locus, downstream of the coding sequence, and separated from it by a T2A sequence. This allowed to maintain Crym endogenous expression and to obtain a spatial and temporal expression of CreER T2 similar to that of endogenous Crym (Fig. 1c) . We then crossed the Crym-CreER T2 line to the TdTomato reporter line (Madisen et al., 2009) , administered a single dose of tamoxifen to P15 double transgenic mice, and sacrificed the animals at P21 to verify Crym-CreER T2 -mediated recombination of the reporter gene ( (Fig. 1d) . To further verify the identity of Td-Tomato-positive cells present in the cortical layers V and VI, we ran a series of immunolabelling and colocalization analyses using optical sectioning by structured illumination (Fig. 1e ). As expected, Td-Tomato expression was restricted to CRYMexpressing neurons and CRE-expressing cells. Td-Tomato also colocalized with CTIP2, a transcription factor expressed at high levels by layer V SubCerPN, and at lower levels by layer VI corticothalamic neurons, and with TLE4 a transcription factor expressed by layer VI corticothalamic neurons (Molyneaux et al., 2007) . Importantly, Td-Tomato did not colocalize with SATB2, a transcription factor that selectively labels callosal projection neurons across all cortical layers (Fame et al., 2011; Molyneaux et al., 2007) , nor with Parvalbumin-positive (PV) inhibitory GABAergic interneurons (Tremblay et al., 2016) (Fig. 1e) . To further test whether the chosen strategy could induce recombination within the disease-relevant CSN, we further retrogradelly labelled this neuronal population in the Crym-CreER T2 ;TdTomato double transgenic mice by injecting of Fluorogold (FG) within the cervical portion of the dorsal funiculus. Microscopic analyses in the cortical layer V of the motor cortex revealed colocalization of TdTomato with FG (Fig. 1f) . Finally, we verified the absence of recombination within the spinal cord. As expected, Td-Tomato positive corticospinal tract (CST) was detected in the ventral part of the dorsal funiculus, but no Td-Tomato positive cell could be detected within the white or the grey matter (Fig. 1g) . Importantly, ChAT-positive MN of the ventral horn were devoid of Td-Tomato expression (Fig. 1g) (Fig. 2a) . All animals received a single dose of Tamoxifen at P15 (Fig. 2a) . To verify SOD1 G37R transgene excision in the cortical layer V of CrymSOD1 animals, compared to their SOD1 littermates, we microdissected the cortical layers II/III and V, along with the brainstem and spinal cord of four months old, extracted mRNA and genomic DNA and ran respectively RT-qPCR and PCR (Fig. 2b ).
We observed a significant decrease of SOD1 G37R transgene expression selectively within layer V of the cerebral cortex, and not in the layer II/III or the spinal cord (Fig. 2c) . Similarly, we quantified a significant decrease of SOD1 G37R transgene within the genomic DNA extracts from the cortical layer V but not in the cortical layer II/III, the brain stem or the spinal cord (Fig. 2d) .
As expected, ablation of SOD1 G37R transgene within the cortical layer V is not complete, given the selected expression of the Cre recombinase in only a subpopulation of neurons, i.e. the SubCrePN, and not in the other neuronal and glial populations, i.e. the excitatory callosal projection neurons, inhibitory interneurons, astrocytes, microglia and oligodendrocytes (Lodato et al., 2014) . Together, the data suggest that our strategy to excise SOD1 G37R transgene from CSN, and more broadly SubCerPN and other CFuPN, is efficient.
Selective removal of SOD1 G37R from CSN prevents their neurodegeneration without affecting the surrounding reactive gliosis
Degeneration of the CSN is a hallmark of ALS and has been reported in different mutant SOD1 mouse models of the disease (Marques et al., 2019; Ozdinler et al., 2011; Zang and Cheema, 2002 and at disease end-stage (21.79 ± 6.60 % loss, p=0.0096) (Fig. 3b,c CrymSOD1 and their aged-matched control littermates to reveal the astrogliosis marker GFAP, and the microgliosis marker IBA1 (Fig. 3d,f) . Immunofluorescence analysis revealed an overall mild increase of GFAP and IBA1 immunoreactivity, that appeared as discrete patches, in SOD1
and CrymSOD1 compared to control (Fig. 3d,f) . Because increased GFAP and IBA1
immunoreactivity seemed more particularly restricted to the cortical layer V, we further quantified their intensities within this layer, along with the cortical layer II/III (Fig. 3e,g CrymSOD1 animals (p=0.8738) (Fig. 3.f) . Taken in their whole, the data suggest that SOD1
G37R
expression by CSN is sufficient to induce their degeneration in a cell-autonomous manner. In addition, CSN degeneration and local (cortical layer V) reactive gliosis appear to be independent from each other: reactive gliosis is neither a cause nor a consequence of CSN degeneration.
Selective removal of SOD1 G37R from the CSN limits spasticity
Degeneration of CSN (or upper motor neurons) leads to the development of the "upper motor neuron syndrome" characterized by decreased motor control, muscular weakness, altered muscle tone, clonus, spasticity and other manifestations of hyperreflexia (Ivanhoe and Reistetter, 2004; Purves et al., 2004; van Es et al., 2017) . To test whether maintenance of the CSN population could impact spasticity, we recorded the long lasting tail muscle activity following cutaneous stimulation in awake and fully paralyzed SOD1 and CrymSOD1 animals prior to harvesting (Bennett et al., 1999; Dentel et al., 2013; Oussini et al., 2017) (Fig. 4a-c) .
Within the CrymSOD1 group, frequency of spastic mice was lower than within the SOD1 group, but the difference did not reach significance (76.92% vs 90.91% respectively, p=0.5963) (Fig.   4b) , however, the amplitude of the response was significantly smaller within the CrymSOD1 group than within the SOD1 one (0.3108 ± 0.0492 vs 0.4870 ± 0.0654, p=0.0452), suggesting that SOD1 G37R excision from the CSN and maintenance of the CSN population was sufficient to limit spasticity (Fig. 4c ).
In the FloxedSOD1 G37R mouse model, spasticity has previously been linked to serotonergic neuron degeneration in the raphe nuclei (Dentel et al., 2013; Oussini et al., 2017) . We thus tested whether the decreased levels of spastic response that we recorded with the tail LLR could be at least partly attributed to a limited degeneration of serotonergic neurons. We quantified the number of TPH2-positive neurons present in the dorsal raphe nucleus (DR) and the median raphe and raphe magnus nuclei of end-stage SOD1 and CrymSOD1 and their control littermates, WT & CrymCre (Fig. 4d-f ). We did not detect any difference in the median raphe and raphe magnus nuclei across genotypes (Fig. 4e,f) . However, we observed a significant loss of TPH2-positive neurons of SOD1 and CrymSOD1 animals compared to WT & CrymCre animals in the dorsal raphe nucleus (SOD1: loss of 30.14 ± 6.02, p<0.0001 and CrymSOD1: loss of 35.98 ± 6.40; p<0.0001) (Fig. 4e,f) . This loss was accompanied by an enlargement of the aqueduct in the SOD1 and CrymSOD1 mice compared to WT & CrymCre mice (Fig. 4e, arrows) . However, no significant difference in the number of dorsal raphe nucleus TPH2-positive neurons could be observed between SOD1 and CrymSOD1 animals (p=0.7057) (Fig. 4f) . Together, the data suggest that in the FloxedSOD1 G37R mouse line, intensity of the spastic tail LLR can be at least partly attributed to CSN dysfunction and/or degeneration, and not only to serotonergic neuron degeneration.
Maintenance of the CSN population does not impact ALS-like symptoms onset and progression
Next, we sought to test the effect of CFuPN-selective ablation of SOD1 G37R on the manifestation of ALS-like symptoms in our mice, i.e. weight loss, disease onset, premature death and motor impairment (Fig. 5) . As already reported (Boillee et al., 2006) , SOD1 mice stopped gaining weight (Fig. 5a ), started progressively losing weight, which we considered to be the onset of the disease from 160 days on (Fig. 5b) , and died prematurely from 410 days on (Fig. 5c ). While
CrymSOD1 animals were slightly but significantly lighter than their SOD1 littermates (Fig. 5a, p=0.0121), we did not detect any difference between SOD1 and CrymSOD1 animals regarding disease onset (Fig. 5b p=0 .4527) and survival ( Fig. 5c p=0.2152). Motor performance analyses revealed no difference between the SOD1 and CrymSOD1 groups regarding the evolution of the grip strength of the animals (Fig. 5d, p=0.1434 ), or the time when it started decreasing (Fig. 5e,   p=0 .1114). However, CrymSOD1 animals performed significantly better than their SOD1
littermates on the inverted grid test with a longer latency to fall (Fig. 5f, p<0 .0001), a delay of the age at which animals had lost 25% (Fig. 5g, p=0 .0004) or 50% of their initial latency to fall (Fig. 5h, p=0 .0335), and a higher holding impulse (Fig. 5i, p=0 .0009). Contrastingly, Catwalk analyses of the gait revealed no difference between SOD1 and CrymSOD1 animals regarding the run average speed (Fig. 5j, p=0 .3140), the hind limbs "stand index" (Fig. 5k, p=0 .0989), "max contact max intensity mean" (Fig. 5l, p=0 .3238), "max contact mean intensity mean" (Fig. 5m,   p=0 .2483), "print area" (Fig. 5n, p=0 .9311) and "stride length" (Fig. 5o, p=0 .2803). Taken in their whole, the data indicate that deletion of SOD1 G37R from the CFuPN, and maintenance of the CSN population has no impact on disease onset, and survival, and only ameliorates discrete motor functions.
Maintenance of the CSN population does not prevent or delay muscle denervation or spinal pathology
Next, we tested whether ablation of the SOD1 G31R transgene from the CSN and related corticofugal neurons had an impact on the muscular and spinal manifestations of the disease.
We first ran electromyographic recordings on the gastrocnemius and tibialis muscles of both hind limbs of end-stage SOD1 and CrymSOD1 animals and their WT and CrymCre age-matched control littermates (Fig. 6a,b) . Innervated muscles were given a score of 0, denervated muscles a score of 1 and the sum of the score of the four muscles was calculated for each animal (Fig.   6b ). Denervation was clearly observed in SOD1 and CrymSOD1 mice compared to the WT and
CrymCre controls, but no significant difference was observed between SOD1 and CrymSOD1 mice (SOD1: 3.75 ± 0.179; CrymSOD1: 3.21 ± 0.317; p=0.0809; Fig. 6b ). To further assess the innervation status of the muscles, we labelled the neuromuscular junctions (NMJ) of the tibialis anterior muscle of end-stage SOD1 and CrymSOD1 mice and controls WT and CrymCre (Fig. 6c) .
Rating of the NMJ integrity into three categories, innervated, partly denervated and fully (Fig. 6f,g ). Spinal MN degeneration upon SOD1 G37R overexpression in SOD1 and CrymSOD1 mice was accompanied with increased levels of hSOD1 protein that appeared as aggregates, together with astrocytosis, microgliosis and altered autophagy as revealed by increased immunolabelling of GFAP IBA1 and P62 respectively (Fig. 7a,c,e,g ). Quantification of the fluorescence intensity of these different pathology markers revealed again similar extents of pathology between SOD1 and CrymSOD1 animals, both in the white and grey matter (Fig. 7b,d 
Discussion
We previously demonstrated that absence of CSN and other SubCerPN was beneficial in a mouse model of ALS, suggesting that these populations of CFuPN were detrimental in a context of ALS, and bringing first experimental evidence of the corticofugal hypothesis of the disease . In the present study, we thought to determine how cell-autonomous expression of a mutant toxic transgene i) could impact CSN survival, and ii) could contribute to the detrimental effect carried by the CFuPN in the peculiar context of ALS. We thus generated a CrymCreER T2 mouse line in order to selectively allow expression of the Cre recombinase in CFuPN and excision of the toxic SOD1 G37R transgene (Boillee et al., 2006) from this diseaserelevant neuronal population. We demonstrated that genetic ablation of the mutant SOD1
G37R
transgene from the CFuPN was sufficient to prevent the loss of CSN, suggesting that CSN degeneration mostly relies on cell-intrinsic mechanisms. However, genetic ablation of SOD1
from CFuPN had no effect on disease onset and survival, indicating that toxicity of the CFuPN in ALS, and corticofugal propagation of the disease are probably not mediated by the presence and possible propagation of misfolded mutant proteins, but more likely by other aspects of the cortical pathology, one possibility being cortical hyperexcitability.
Floxed SOD1 G37R mice recapitulate loss of CSN
Progressive degeneration of the CSN translates into a series of symptoms grouped under the term of upper motor neuron syndrome, a hallmark of the clinical manifestation of ALS (Ivanhoe and Reistetter, 2004; Purves et al., 2004) . Post mortem analyses of the motor cortex of ALS patients confirms the loss of CSN, or Betz cells (Charcot, 1874; Nihei and Kowall, 1993) . Similarly numerous rodent models of the disease recapitulate CSN degeneration such as the C9-BAC mice (Liu et al., 2016) , the hPFN1 G118V mice (Fil et al., 2016) , the TDP43 A315V mice (Herdewyn et al., 2014; Wegorzewska et al., 2009) , and the TDP43 G298S mice (Müller et al., 2019) and the SOD1 G93A rats (Thomsen et al., 2014) , and SOD1 mouse models also display progressive loss of CSN that starts pre-symptomatically (Marques et al., 2019; Ozdinler et al., 2011; Yasvoina et al., 2013; Zang and Cheema, 2002) . In the Sod1 G86R mouse model of the disease, we further demonstrated that CSN start degenerating long before first signs of MN degeneration can be observed and that CSN and MN degeneration are somatotopically related. Indeed, in the cerebral cortex, lumbar-projecting CSN are affected earlier than the rest of the population, similarly to lumbar MN being affected earlier than the rest of the population in this model (Marques et al., 2019) . Here, by sampling the subpopulation of lumbar-projecting CSN, we demonstrated that the FloxedSOD1 G37R mice recapitulate CSN degeneration as well.
In Floxed SOD1 G37R mice, CSN degeneration follows cell-autonomous mechanisms
Genetic ablation of the SOD1 G37R transgene was sufficient to prevent loss of CSN suggesting that CSN degeneration was independent from its SOD1 G37R -expressing environment, i.e. other cortical neurons, astrocytes, microglia, oligodendrocytes along their axons and final neuronal targets in the spinal cord, in accordance with strictly cell-autonomous mechanisms. Similar cellautonomous mechanisms were described for the brainstem serotonergic neurons , but not for the spinal MN whose survival rather reflects combination of cellautonomous and non-cell autonomous mechanism (Boillee et al., 2006) . Thus, SOD1
G37R
transgene expression differentially affects neuronal survival depending on the nature of the neuronal population. Interestingly, reactive astrogliosis and microgliosis were very moderate in the motor cortex of the FloxedSOD1 G37R animals in comparison with their spinal cord. Cortical astrogliosis appeared as discrete patches, while microgliosis rather corresponded to a two-fold increase of IBA1 expression, and these were selectively found in the layer V of the motor cortex were CSN reside. Surprisingly, maintenance of the CSN population by selective removal of the SOD1 G37R transgene had no impact on reactive gliosis, suggesting that astrogliosis and microgliosis were not secondary to CSN degeneration. Similarly, maintenance of astrogliosis and microgliosis in the cortical layer V of the CrymSOD1 animals at similar levels than the SOD1 animals did not prevent the cell-autonomous beneficial effect of SOD1 G37R ablation on CSN survival, suggesting that CSN degeneration is not secondary to reactive gliosis either. Overall, this suggests that CSN degeneration and cortical reactive gliosis are rather independent from each other. The precise co-localization, within the cortical layer V, of CSN degeneration and reactive gliosis remains nevertheless quite remarkable. These results are in opposition with what has been described so far in the spinal cord, i.e. the well-described interaction between cell-autonomous and non-cell autonomous mechanisms on spinal MN survival, and the toxic role of astrocytes, microglia and Schwann cells on MN (reviewed in (Ilieva et al., 2009; Serio and Patani, 2017) . The discrepancy between cortical and spinal glial contribution to neighbouring CSN and MN survival may arise from the level of gliosis itself, rather moderate in the cerebral cortex and important in the spinal cord, or from the actual nature of the targeted neuronal populations, which have little in common besides being targeted by ALS.
Together, the data strongly suggest that the mechanisms that govern MN degeneration may not be directly transposable to CSN degeneration, and that it is worth further investigating these aspects, as we recently started (Marques et al., 2019) .
Of possible mechanisms of disease propagation by CFuPN
Several clinical features support a cortical origin of ALS (Eisen et al., 2017; and recent longitudinal imaging analyses suggest a propagation of impairments along the corticofugal tracts (Kassubek et al., 2014; Verstraete et al., 2013) . We recently provided the first experimental evidence of the corticofugal hypothesis by showing that absence of SubCerPN, the most important output of the cerebral cortex, delayed disease onset and extended survival in the Sod1 G86R mouse model of the disease . However, whether corticofugal dissemination of the disease relies on prion-like transmission of misfolded proteins or on altered neuronal excitability and subsequent excitotoxicity (Vucic and Kiernan, 2017) remains an open question. Here, we show that ablation of mutant SOD1 G37R transgene from CFuPN had no effect on disease onset and survival. This rules out the possibility of corticofugal propagation of misfolded proteins in a prion-like manner. A few years ago, Thomsen and colleagues knocked-down mutant SOD1 transgene in the posterior motor cortex of the SOD1 G93A rat model of ALS (Thomsen et al., 2014) , using an AAV9 virus that selectively transduces neurons. This strategy delayed disease onset and extended survival. It is possible that the beneficial effect was reached not upon targeting the excitatory CFuPN, but also upon targeting inhibitory interneurons (INs) , that modulate excitability and activity of CFuPN and other cortical excitatory neurons (Lodato et al., 2014; Tremblay et al., 2016) . In the 
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As opposed to the absence of SubCerPN in Sod1 G86R mice , or the knock-down of SOD1 G93A in the motor cortex of transgenic rats (Thomsen et al., 2014) , genetic ablation of SOD1 G37R from CFuPN had no effect on ALS-like symptoms onset and survival.
Together, these studies suggest that CFuPN are toxic in a context of ALS, and that their toxicity is not mediated by their cell-autonomous expression of a mutant transgene, but more likely by that of their environment. Because CSN survival and cortical reactive gliosis seemed to be independent from each other, alternative candidates to toxicity could be the populations of INs for their contribution to hyperexcitability (Vucic and Kiernan, 2017) . Indeed, cortical hyperexcitability, revealed by transcranial magnetic stimulation, is an early feature of sporadic and familial ALS, appears in SOD1 mutant carrier prior to clinical onset of the disease (Vucic, 2006) , and is negatively correlated with disease progression and survival (Shibuya et al., 2016) .
Selective silencing of the CFuPN, or selective transgene excision from the INs may in the future contribute to a better understanding of the role of cortical hyperexcitability in ALS, and potentially unravel new therapeutic targets. (f) and P62 (h) specific signal in the grey and white matters of the spinal cord. £ p<0.05, *** or ### p<0.001 and ns: non-significant in 2-way ANOVA followed by Tukey's multiple comparisons test.
